Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Company Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
394.3 USD +0.20% Intraday chart for Vertex Pharmaceuticals Incorporated -0.57% -3.10%
Apr. 18 Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain MT
Apr. 17 UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating MT

Business Summary

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.

Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Number of employees: 5,400

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
8,931 100.0 % 9,869 100.0 % +10.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
61.2 %
5,699 63.8 % 6,040 61.2 % +5.98%
Europe
31.5 %
2,706 30.3 % 3,109 31.5 % +14.91%
Other
7.3 %
526 5.9 % 720 7.3 % +36.87%

Managers

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Charles Wagner DFI
 Director of Finance/CFO 55 19-04-09
Mike Tirozzi CTO
 Chief Tech/Sci/R&D Officer - 18-12-31
Carmen Bozic CTO
 Chief Tech/Sci/R&D Officer 61 19-04-30
Stuart Arbuckle COO
 Chief Operating Officer 58 12-09-03
Mark Bunnage CTO
 Chief Tech/Sci/R&D Officer - 15-12-31
Edward Atkinson CTO
 Chief Tech/Sci/R&D Officer 58 20-06-30
David Altshuler CTO
 Chief Tech/Sci/R&D Officer 59 14-12-31
Susie Lisa IRC
 Investor Relations Contact - 22-08-31

Members of the board

Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 17-06-07
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Bruce Sachs BRD
 Director/Board Member 64 97-12-31
Terrence C. Kearney BRD
 Director/Board Member 69 11-05-16
Lloyd Carney BRD
 Director/Board Member 62 19-02-20
Michel Lagarde BRD
 Director/Board Member 50 23-10-04
Sangeeta Bhatia BRD
 Director/Board Member 55 15-06-17
Diana McKenzie BRD
 Director/Board Member 59 20-06-02
Suketu Upadhyay BRD
 Director/Board Member 55 22-05-17
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 258,459,343 258,168,408 ( 99.89 %) 0 99.89 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
10.03 %
25,902,938 10.03 % 10 828 M $
Vanguard Fiduciary Trust Co.
8.626 %
22,282,180 8.626 % 9 314 M $
Capital Research & Management Co. (World Investors)
8.442 %
21,805,770 8.442 % 9 115 M $
BlackRock Advisors LLC
6.631 %
17,127,237 6.631 % 7 159 M $
Fidelity Management & Research Co. LLC
5.023 %
12,974,299 5.023 % 5 423 M $
STATE STREET CORPORATION
4.678 %
12,083,818 4.678 % 5 051 M $
AllianceBernstein LP
2.831 %
7,313,099 2.831 % 3 057 M $
T. Rowe Price International Ltd.
2.279 %
5,887,412 2.279 % 2 461 M $
Geode Capital Management LLC
2.196 %
5,673,419 2.196 % 2 372 M $
JPMorgan Investment Management, Inc.
2.158 %
5,575,361 2.158 % 2 331 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000233 %
2,404 0.000233 % 251 487 $
XP Allocation Asset Management Ltda.
0.000070 %
727 0.000070 % 76 053 $

Company contact information

Vertex Pharmaceuticals, Inc.

50 Northern Avenue

02210, Boston

+617 341 6100

http://www.vrtx.com
address Vertex Pharmaceuticals Incorporated(VRTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
393.5 USD
Average target price
460.3 USD
Spread / Average Target
+16.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.23% 8.57B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Company Vertex Pharmaceuticals Incorporated